Review Article

ScienZTech

International Journal of Review in Life Sciences

Published by ScienzTech Publication Journal Home Page: www.scienztech.org/ijrls

A Review on Microsponge Drug Delivery System

Bharathi M*, Mullaikodi O, Rajalingam D, Gnanasekar N, Kesavan M

Kamalakshi Pandurangan college of Pharmacy, Tiruvannamalai, Tamilnadu, India-606603

Article History:

Received on: 10 May 2020
Revised on: 12 Jun 2020
Accepted on: 25 Jun 2020
Published on: 08 Jul 2020

Volume: 10 Issue: 2

Keywords:

Microsponge,
Polymer,
Application

Abstract

A Microsponge (MS) is an extremely interconnected, permeable, polymeric structure that involves permeable microparticles trapping and discharging through the skin for a considerable time period. Drug delivery system (DDS) offer extended discharge with less degradation, improved physical stability along with better tolerance. The main intend of any DDS is to achieve the required amount of drug in plasma to produce the desired therapeutic and non-poisonous effect over a prolonged period of time. Specific methods for preparing MS were reviewed in this current investigation, and their pharmaceutical implementations were signed. MS have major DDS point of interest. It also improves stability, increased flexibility in formulation and increased elegance. In fact, numerous studies have reported that MS supplies are not allergic, mutagenic, and poisonous. MS creativity is used in products such as sunscreen, prescription, cosmetics, and OTC skin care. This inquiry primarily focuses on the different methods used to identify, plan and exploit MS.

*Corresponding Author

Name: Bharathi M
Phone: 9944800384
Email: Barathihari.mohan@gmail.com

eISSN: 2231-2935

DOI: https://doi.org/10.26452/ijrls.v10i2.1280

Production and Hosted by

ScienzTech.org

INTRODUCTION

The DDS scene has been extraordinarily vibrant and rapidly developing to integrate an ever-increasing number of distribution system changes to streamline efficiency and price-adaptation. The rapid development of drug delivery discovery is accelerating emerging pharmaceutical developments (DNA-based therapeutics, peptides, and proteins). Classically these new drugs cannot be transmitted effective by normal means. DDS can handle discharge levels or target drugs to a specific organ. [1]

Today, developing new drugs is not enough for the treatment of medication. Be that as it may, it also involves designing and creating the most appropriate DDS at the site of operation. The drug's in-vivo fate is not only firm by the property of the drug, but also regulated by the transporter system, enabling a humiliated release and locating the medication as indicated by the specific procedure. The chief state-of-the-art test is to conduct a check on the drug DDS through various ongoing advances achieved by far-reaching research. [2]

MSs are microscopic spherical particles proficient of absorbing skin discharges or secretions, sinking sleekness and skin shine in this way. Sphere shaped components consisting of a bunch of flat small spheres fitted with numerous grasping loads in skin discharges. MS, which is generally offered to the customer in customary structures such as gels, creams or moisturizers and also contains a reasonably high amount of active ingredient. [3]

The MS is an untested polymeric structure composed of permeable microspheres, small spherical particles contains a multitude of interlocked void inside a capsule with a huge surface so that drug diffuses in a controlled manner. The diameter of the MS varies from 5-300μm, including 250000 pores and 10 foot long interior pores, giving an absolute void of approximately 1ml / g broad medium reservoir. The

surface area of the MS varies from 20 to 500 m^2/ g and the void expansion from 0.1 to 0.3cm^3/g [4–6].

Necessities that a microsponge should meet

If the drug is routinely non-polar,be recognized as porogen to allow the permeable structure. It should be insoluble in water, or at most just slightly miscible. Monomers and polymers will be inactive. When it comes to impetus of polymerization, polymerization environment, it should be steady. Drug discharge controls by dispersion or otherwise activates, for example, temperature, pressure, pH and humidity [7].

Characteristics of microsponges

On apply to the skin; it slowly discharges its drug substance to the skin over a time period and even in response to extraordinary effectiveness and least aggravation, for example, temperature, rubbing and pH impact and so on. Highlights of MSs are as per the following: [6, 8, 9]

1. Those formulations were consistent over a pH 1 to 11 range.
2. They showed steady temperature of up to 130^0C.
3. Many of the components and vehicles are cool.
4. Since its small pore size of 25 μm it won't enable the micro organism to reach the pores, so they are self-sterilized.
5. They also expanded the potential for trapping by 50 to 60 per cent.
6. They were financially savvy and free streaming.
7. The MSs Particles are disproportionately large, they are clumped together to be swallowed through the skin.
8. It is good value for money
9. For example extended discharge gives steady operation as long as 12 hours.
10. We have greater adaptability to the formulations.

Precondition for formulating the material into an MS

1. This should be fully soluble in monomer or, if not, soluble in co-solvent additions
2. This should be insoluble or easily slightly dissolvable in water.

Methods of preparation

In view of their physicochemical properties of the medication which is joined in the development of MSs utilizing two strategies one will be one step and the other is two-step processes. The active medication which is steady to free radicals is entangled by one step procedure.

Polymerization method in one step

In this strategy, the monomers are broken up with drug (non polar) in proper dissolvable of monomer, which further scatter in aqueous phase with tumult. In this aqueous phase option of surfactants and suspending specialists are added to encourage the formation

Liquid-liquid suspension polymerization

The MS are formulated by liquid- liquid suspension . This is shaped with particular droplet of supported size then polymerization is expressed by impetus by increment in temperature. A store kind of framework that opens through pores at the surface due to polymerization. An inactive fluid insoluble with water and soluble with monomer is utilized to frame pore network.

After end of polymerization process the liquid is separated from MS and infuse within performed MS and then fit in various active ingredients that act as a topical carrier. For the efficient and earlier insertion of functional substances solvent can be used. Two-step processes are utilized and polymerization is perform by porogen and replaced by functional group if the drug is susceptible to polymerization. [10]

Quasi-emulsion solvent diffusion

MSs are often prepared using the diverse polymer by means of quasi-emulsion solvent diffusion technique. Two stages correlated with this, i.e. one is internal and the other is external. Inner step-The RS 100 Eudragit was broken down into ethyl alcohol.

Medication is subjected to this solution and dissolved at 350 Outer phase PVA solution is applied with water by ultrasonic process. MSs are then dried for 12hrs in a hot air broiler at 400C and the weight is determined [11] .

Evaluation of Microsponge

Particle size Analysis

Laser light diffractometry or any other appropriate technique will conduct molecular size analysis of stacked and empty MSs. Complete percentage of drug discharge from MSs of various molecule sizes will be plotted against time to analyze the impact of molecule size on discharge of medicines. Particles larger than XY μm will impart abrasive propensity and particles of size between PQ and 25 μm

should be used in the final effective topical formulation [12, 13].

Morphology and surface topography of microsponges

Isolated MSs are coated with gold palladium when the argon is present at RT and MSs Surface morphology is done by scanning electron microscopy (SEM).

Determination of loading efficiency and production yield

The loading efficiency (%) of the MSs determined by accompanying condition:

$$\text{Loading efficiency} = \frac{\text{Actual Drug Content in MSs X 100}}{\text{Theoretical Drug Content:}} \quad \ldots. (1)$$

The production yield of the MSs can be dictated by computing precisely the preliminary weight of the crude resources and the end product weight of MS acquired.

$$\text{Production Yield} = \frac{\text{Practical mass of MSs X 100}}{\text{Theoretical mass (Polymer and drug).}} \quad \ldots. (2)$$

Characterization of pore structure

The porosimetry of mercury penetration used to consider the effect of pore calculation, i.e. diameter and volume with the rate of discharge from MSs. Porosity boundaries of MSs, e.g. total porous surface area, percent filled porosity, bulk and apparent density, poral shape and morphology, intrusion–isothermic extrusion pore size distribution, average pore diameter, percent porosity

Dissolution tests

Dissolution apparatus USP XXIII with 5μm mesh basket is used for the dissolution test. The medium of dissolution is selected based on the solubility of the active material and also guarantees the sink state. The samples are evacuated and checked by appropriate analytical techniques at various stretches of the medium.

Determination of true density

Through means of repeated calculation true density is measured in the presences of helium gas with the aid of ultra pycnometer.

Viscoelastic properties

MSs' durability (visco elastic properties) can be modified to provide more gentle or firmer beadlets as indicated by the final formulation requirements. Expanded cross-connection would slow down discharge speeds in general.

Advantages of Microsponge DDS

- This prevents active ingredient accretion in the epidermis and dermis.
- Reduces discomfort of a successful medication by preserving its effectiveness.
- It complies well with patients.
- Improves drug living time on the skin surface or in the epidermis.
- Stable at pH 1 to 11, temperatures as low as 120^{o}C.
- Most of the vehicles and ingredients matched well.
- It improves the elegance of the products.
- This has the potential to enhance medication bioavailability.
- It has superior versatility in formulation [14, 15] .

Applications of Microsponge

Topical

MDS depends on various skin formulations. MS is polymer-based which allows a huge substance of medication to be binding or maintained. This is because of its permeable structure, where around 250000 pores are present in 1ml/g. This result in its ability to convey more drugs compared to other DDS, especially in skin preparation, also builds the medication residence time in the epidermis zone [16–18] .

It is considered to decrease its long-term use, decrease the duration, decrease the absorption into systemic flow and decrease its skin symptoms such as dermatitis, hypersensitivity and rash. Another approach to preventing these reactions is the use of perfect, organically idle polymer which is not recognized as a toxic to the body. Therefore the polymers used must be non-allergenic, non-poisonous and non-mutagenic [19–21] .

Oral

Due to its easy entry, high capacity to dissolve many drugs, and low harmfulness, the drug administration through oral route is most widely and frequently used. Given the fact that easy and safe, it is not ideal for all handled medications, such

as medicines that have short lifetime that are discharged quickly after administration, medications that are pulverized by the corrosiveness of the stomach or bile juice released in the digestive tract, or the colon disease medication. This offered ascend to the creation of controlled methods for releasing the medication.

Numerous medications were designed as MS which brought about high points of interest in this route of administration as opposed to microspheres, nano particles liposomes and so forth not resisting its permeable structure, miniaturized sponges display longer lag time which can advance colon focusing by securing the medication against acridity of the stomach and bile emissions in the small intestine as it just discharges the medication at colon PH [22–24] .

Future aspects

Tissue engineering

Among many other fields Tissue Engineering is the most encouraging fields, as researchers accepted to improve personal satisfaction of patients.In which Vascular Tissue Engineering is one type. For this, the standard path is the use of extended polytetrafluoroethylene (ePTFE) or Dacron, scientifically used for the reconstruction of large-diameter arteries, such as the iliac vein and aorta.

These are inadequate for small artery, so it is known to induce occlusion by outside bodies. To overcome this bypass method is required with increasingly careful mediation. Using Scaffold Development technique, a recently designed small gage vascular device made of poly-L-lactic acid (PLLA) fibers and polyglycolic acid (PGA) aggravated with collagen MS to frame a vascular fixing material and tested on dogs [25–27] .

RNAi

RNAi or RNA interference, is specific characteristic barrier component that has developed to get rid of the infections from RNA which is caused by RNA virus and malignant growth. As an intruder cells can perceive double stranded RNA (dsRNA). At that point one SiRNA strand binds to an objective viral mRNA to interfere with its expression in a sequence-specific manner. There are numerous difficulties, for example, administrative barrier, immune reaction and wellbeing and delivering adequate dose without the requirement for frequent dosages. Because of past difficulties, MS was viewed as the suitable delivery system to defeat these difficulties by utilizing a DNA template technique with rolling circle transcription of. The RNA polymers emerge in a solution containing RNA polymerase, RNA-producing protein and RNA building block (nucleoside triphosphates, NTPs) with circular DNA of rolling circle transcription.

At that point entrapped and turned fibrils, wrinkled sheets with semi-circular structures and lamellar sheets and are shaped. Polycationic polyethylenimine (PEI) causes the RNAi micro sponges to consolidate into 200-nm diameter PEI-covered micro sponges which contain approximately every 500,000 siRNA precursors [28–30] . The release discharged volume versus time was used to determine the mechanism for the drug discharge and to discern the contrasts in the release profile between MSs. The discharge information was examined with the accompanying numerical models:

$$\mathbf{Q = k1tn \ or \ logQ = logk1 + nlogt \ldots Eq(1)}$$

Where Q is the measurement of discharge at time (h), n is the exponent for diffusion which demonstrates the discharge process, and k1 is a constant characteristic of the medication polymer communication.

From the slope and intercept of the log Q plot versus log t, kinetic boundaries n and k1 were identified for correlation purposes as well as for Equation (2), which might be viewed as a straightforward, Higuchi type condition [31, 32].

$$\mathbf{Q = k2t0 : 5 + C \ldots Eq(2)} \quad (2)$$

Equation (2) will provide a straight line discharge profile for discharge information dependent on the square root of time, with k2 being added as a constant of the root time dissolution rate and C being a constant.

Safety Considerations

- Safety investigations of MSs can be affirmed by;
- Allergenicity in guinea pigs
- Visual disturbance investigation in rabbits
- Toxicity for microscopic organisms
- Oral poisonousness investigation in rodents
- Skin bothering investigation in rabbits.

Recent developments in Microsponge DDS

Specific developments were made by modifying nanoferrosponges, nano sponges and permeable micro beads to form the strategies. β-CD nanosponges that can be used for both hydrophilic and lipophillic drugs, rather than polymeric microphones or nanosponges, have been introduced. Such driven structures were investigated for the

drug model serum albumin, flurbiprofen, doxorubicin hydrochloride, dexamethasone and itraconazole administered by mouth. These nanosponges were produced with biphenylcarbonate through a cross-connected reaction of the β CD atom with. Specialists further found that joining a nanosponge with a transporter cytotoxic system might raise the strength of the drug, indicating that such carriers may be use to kill tumor cells [33] .

CONCLUSIONS

The market holds tremendous strength for MS creativity and the flexibility they bring with interest in innovative and deeply successful cosmetic products as well as pharmaceutical. When formulators think about new and creative approaches to delivering active ingredients, they will appreciate the potential of excellent materials offer improved stability, enhanced protection, and reduced reactions from active ingredients, enhanced multifunctionality and enhanced flexibility of ingredients.

Supplemented by novel development, the methods of formulating come close and imaginatively. MSs have a specific advantageous role for the healing of topical diseases; special invention for the controlled release of topical agents, which are often used for the delivery of biopharmaceutical and oral drugs. It shows worthwhile by non-harmful, non-mutagenic, non-aggravation over different objects. So MS has a lot of prospective and is a growing area to be explored with most research analysis later on.

ACKNOWLEDGEMENT

The authors are thankful to all who have extended their constant support for the completion of the work.

Funding Support

The authors declare that they have no funding support for this study.

Conflict of Interest

The authors declare that they have no conflict of interest for this study.

REFERENCES

[1] Shaha V, Jain H, Jethva K, Patel P. Microsponge drug delivery: A Review. Int J Res Pharm Sci. 2010;1(2):212–218.

[2] Kydonieus AF, Berner B. Transdermal Delivery of Drugs. CRC Press Boca Raton. 1987;.

[3] Kaity S, Maiti S, Ghosh A, Pal D, Ghosh A, Banerjee S. Microsponges: A novel strategy for drug delivery system. Journal of Advanced Pharmaceutical Technology & Research. 2010;1(3):283–283. Available from: 10.4103/0110-5558.72416.

[4] Embil K, Nacht S. The Microsponge® Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. Journal of Microencapsulation. 1996;13(5):575–588. Available from: 10.3109/02652049609026042.

[5] Nacht S, Kantz M. The microsponge: A novel topical programmable delivery system. Top Drug Deliv Syst. 1992;42:299–325.

[6] Won R. Utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredients as a Porogen. Method for delivering an active ingredient by controlled time release . 1987;4690825.

[7] Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Control of Prolonged Drug Release and Compression Properties of Ibuprofen Microsponges with Acrylic Polymer, Eudragit RS, by Changing Their Intraparticle Porosity. Chemical & Pharmaceutical Bulletin. 1992;40(1):196–201. Available from: 10.1248/cpb.40.196.

[8] Aritomi H, Yamasaki Y, Yamada K, Honda H, Koshi M. Development of sustained release formulation of chlorpheniramine maleate using powder coated microsponges prepared by dry impact blending method. Journal of Pharmaceutical Sciences and Technology. 1996;56(1):49–56.

[9] Parthiban KG, Manivannan R, Krishnarajan D, Chandra S, Nidhin R. Microsponge role in novel DDS. Intl J Pharm Res Devel. 2011;3(4):117–125.

[10] Article R. Review Article Microsponge DDS : A Review. International Journal of Parenteral and Dermatology . 2017;1(1):35–44.

[11] Martin A, Swarbrick J, &cammarrata A. Complexation and protein binding. Physical Pharmacy- Physical Chemical Principles in Pharmaceutical Sciences. 1991;p. 527–527.

[12] Patil RS, Kemkar VU, Patil SS. Microsponge DDS : A Novel Dosage Form. Am J Pharm Res. 2012;2(4):227–251.

[13] Mantry S, Bagchi A, Das S, Das S. Microsponge As a Novel Stratergy of DDS. Ujpsr. 2015;1(32):32–38.

[14] Mendelson K, Schoen FJ. Heart Valve Tissue Engineering: Concepts, Approaches, Progress, and Challenges. Annals of Biomedical Engineering. 2006;34(12):1799–1819. Available from: 10.1007/s10439-006-9163-z.

[15] Yokota T, Ichikawa H, Matsumiya G, Kuratani T, Sakaguchi T, Iwai S, et al. In situ tissue regeneration using a novel tissue-engineered, small-caliber vascular graft without cell seeding. The Journal of Thoracic and Cardiovascular Surgery. 2008;136(4):900–907. Available from: 10.1016/j.jtcvs.2008.02.058.

[16] Shopsowitz KE, Young H, Zhou JD, Stephen PT. Composite RNAi-Microsponges Form through Self Assembly of the Organic and Inorganic Products of Transcription. Small. 2014;10(8):1623–1633.

[17] Tatiparti K, Sau S, Kashaw S, Iyer A. siRNA Delivery Strategies: A Comprehensive Review of Recent Developments. Nanomaterials. 2017;7(4):77–77. Available from: 10.3390/nano7040077.

[18] Sato T, Kanke M, Schroeder G, Deluca P. Porous biodegradable microspheres for controlled drug delivery. Assessment of processing conditions and solvent removal techniques. Pharm Res. 1988;5:21–30.

[19] Kilicarslan M, Baykara T. The effect of the drug/polymer ratio on the properties of Verapamil HCl loaded microspheres. Int J Pharm. 2003;252:99–109.

[20] Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–111.

[21] Draize JH, Woodard G, Ho C. Methods for the study of irritation and toxicity of substance es applied topically to the Skin and Mucous Membranes. J Pharmacol Exp Ther. 1944;82:377–389.

[22] Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based Nanosponges for Drug Delivery. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2006;56(1-2):209–213. Available from: 10.1007/s10847-006-9085-2.

[23] S VK, B DP. Software Development and Construction of Log Periodic Dipole Antenna Using MATLAB. IJIREEICE. 2015;3(12):83–87. Available from: 10.17148/ijireeice.2015.31218.

[24] D'Emanuele A, Dinarvand R. Preparation, characterisation, and drug release from thermoresponsive microspheres. International Journal of Pharmaceutics. 1995;118(2):237–242. Available from: 10.1016/0378-5173(94)00384-h.

[25] Jain V, Singh R. Design and characterization of colon-specific DDS containing paracetamol microsponges. Arch Pharm Res. 2011;34(5):733–740.

[26] Roh YH, Deng JZ, Dreaden EC, Park JH, Yun DS, Shopsowitz KE, et al. Inside Back Cover: A Multi-RNAi Microsponge Platform for Simultaneous Controlled Delivery of Multiple Small Interfering RNAs (Angew. Chem. Int. Ed. 10/2016). Angewandte Chemie International Edition. 2016;55(10):3515–3515. Available from: 10.1002/anie.201600877.

[27] Roh YH, Lee JB, Shopsowitz KE, Dreaden EC, Morton SW, Poon Z, et al. Layer-by-Layer Assembled Antisense DNA Microsponge Particles for Efficient Delivery of Cancer Therapeutics. ACS Nano. 2014;8(10):9767–9780. Available from: 10.1021/nn502596b.

[28] Grabow WW, Jaeger. siRNA delivery: Loaded-up Microsponges. Nature materials. 2012;11(4):268–269.

[29] Gu L. A Combination RNAi-Chemotherapy Layer by Layer Nano particle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer. Clinical Cancer Research. 2017;23(23):7312–7323.

[30] Iwai S, Sawa Y, Taketani S, Torikai K, Hirakawa K, Matsuda H. Novel Tissue-Engineered Biodegradable Material for Reconstruction of Vascular Wall. Elsevier BV; 2005. Available from: 10.1016/j.athoracsur.2005.03.139.

[31] Patil SS, V D, A K, SD B. Microsponge DDS : A Novel Dosage Form. Am J Pharm Res. 2012;2(4):227–251.

[32] Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nature Materials. 2012;11(4):316–322. Available from: 10.1038/nmat3253.

[33] Han S, Kim, Lee. Library siRNA-generating RNA nano sponges for gene silencing by complementary rolling circle transcription. Scientific Reports. 2017;7(1):10005–10005.

Cite this article: Bharathi M, Mullaikodi O, Rajalingam D, Gnanasekar N, Kesavan M. **A Review on Microsponge Drug Delivery System**. Int. J Rev. Life Sci. 2020; 10(2): 53-59.